Go Pro

Cencora (COR) Stock Forecast & Price Target

Cencora logo
$309.50 -9.00 (-2.83%)
Closing price 03:59 PM Eastern
Extended Trading
$310.33 +0.83 (+0.27%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
3
Buy
13

Based on 16 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, and 13 have given a buy rating for COR.

Consensus Price Target

$370.85
19.82% Upside
According to the 16 analysts' twelve-month price targets for Cencora, the average price target is $370.85. The highest price target for COR is $440.00, while the lowest price target for COR is $285.00. The average price target represents a forecasted upside of 19.82% from the current price of $309.50.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Analyst Ratings Over Time

TypeCurrent Forecast
9/17/25 to 9/17/26
1 Month Ago
8/18/25 to 8/18/26
3 Months Ago
6/19/25 to 6/19/26
1 Year Ago
9/17/24 to 9/17/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
3 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$370.85$374.25$374.00$311.25
Forecasted Upside19.82% Upside18.29% Upside37.51% Upside7.77% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cencora Stock vs. The Competition

TypeCencoraHealthcare CompaniesBroader Market
Consensus Rating Score
2.81
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside19.82% Upside718.93% Upside17.75% Upside
News Sentiment Rating
Positive News

See Recent COR News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/8/2026
Ryan Halsted
Ryan Halsted
Not Rated
Reiterated RatingSector Perform$330.00+0.91%
8/11/2026
Stephen Baxter
Stephen Baxter
4 of 5 stars
Boost TargetOverweight$331.00 ➝ $395.00+21.85%
8/7/2026
Morgan Stanley logo
Morgan Stanley
3 of 5 stars
Erin Wright
Erin Wright
4 of 5 stars
Boost TargetOverweight$342.00 ➝ $346.00+7.00%
8/7/2026Boost TargetOverweight$382.00 ➝ $390.00+20.86%
8/6/2026 UpgradeHold (C+)Buy (B-)
8/6/2026Set Target$370.00+18.08%
8/6/2026Boost TargetBuy$412.00 ➝ $430.00+35.25%
8/6/2026 Reiterated RatingOutperform$350.00+10.18%
8/6/2026Reiterated RatingBuy
6/24/2026Boost TargetNeutral$280.00 ➝ $285.00-0.80%
6/10/2026Lower TargetOverweight$425.00 ➝ $350.00+25.38%
4/28/2026Initiated CoverageMarket Perform
3/17/2026 Reiterated RatingOutperform
1/22/2026UpgradeUnderperformBuy
11/10/2025Boost TargetBuy$350.00 ➝ $400.00+10.23%
11/6/2025Boost TargetOutperform$340.00 ➝ $380.00+7.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:30 PM ET.


Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 15, 2026. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • Cencora, Inc. recently reported second-quarter earnings that exceeded analyst expectations, posting $4.48 in earnings per share against a consensus estimate of $4.35, while also generating $84.75 billion in revenue, which surpassed the projected $84.31 billion and represented a 5.1% year-over-year increase.
  • The company has a strong consensus rating of "Moderate Buy" from Wall Street analysts, with a consensus price target of $370.85, which suggests significant upside potential from the current stock price of $323.20.
  • Cencora, Inc. recently authorized a $2.00 billion stock buyback plan, signaling that the board believes the stock is undervalued and providing a mechanism to return capital to shareholders by reacquiring up to 3.9% of its outstanding shares.
  • Short interest in the stock has been declining over recent months, with shares shorted dropping to 4,528,193 as of August 31, 2026, indicating that fewer investors are betting against the company's future performance.
  • The company maintains a low beta of 0.57, meaning its stock price tends to be less volatile than the broader market, which can provide a more stable investment profile for risk-averse investors.

Cencora
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • Cencora, Inc. faces regulatory uncertainty regarding its merger with Covetrus, as Royal Bank of Canada noted that the deal is seeing "intensified" scrutiny from the Federal Trade Commission, which could pose risks to the transaction's completion.
  • The company has a high debt-to-equity ratio of 3.53, indicating a significant level of leverage that could limit financial flexibility or increase interest costs if interest rates remain elevated.
  • Recent insider activity has been predominantly negative, with executives such as EVP Elizabeth S. Campbell and CEO Robert P. Mauch selling significant blocks of shares in the past year, which may signal a lack of confidence in the stock's near-term appreciation.
  • The stock is currently trading at a P/E ratio of 24.01, which is relatively high compared to the company's net margin of 0.79%, suggesting that investors are paying a premium for earnings that may not be supported by strong profit margins.
  • Cencora, Inc. has a current ratio of 0.93 and a quick ratio of 0.58, both of which are below 1.0, indicating that the company may face challenges in meeting its short-term financial obligations with its available liquid assets.

COR Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $370.85, with a high forecast of $440.00 and a low forecast of $285.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 19.82% based on their 12-month stock forecasts.

Over the previous 90 days, Cencora's stock had 1 upgrade and 1 downgrade by analysts.

Analysts like Cencora more than other "healthcare" companies. The consensus rating for Cencora is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how COR compares to other companies.


MarketBeat monitors more than a dozen sources for Cencora analyst ratings, with the most recent rating issued on 9/8/2026.
From Our Partners